Development and Validation of RP-HPLC Method for Determination of Thermal Degradation Impurity in Macrolide Immunosuppressant Substance and Drug Product

Authors

  • Nisha Shri Research and Development Center, Analytical Research and Development, Aurobindo Pharma Limited, Hyderabad, Telangana, India
  • J. Balaji Research and Development Center, Analytical Research and Development, Aurobindo Pharma Limited, Hyderabad, Telangana, India

DOI:

https://doi.org/10.37591/rrjodfdp.v3i1.335

Abstract

The present study describes a simple and stability-indicating reverse phase high-performance liquid chromatography (RP-HPLC) method for the quantification of the thermal degradation impurities of Tacrolimus (FK506) namely Ally ester rearrangement impurity (Impurity R) in Tacrolimus capsules and drug substances. Successful separation of impurity R from Tacrolimus, its other related substances and its tautomers were achieved on a Zorbax XDB C8 (150×4.6 mm, 5 μm) and detector of UV at 210 nm, 2.0 ml/min as a flow rate, and 20 μl as an injection volume. For the RP- HPLC method, 0.1% Trifluroacetic acid in water and Acetonitrile was used as a binary linear gradient and the column temperature was 55° C. Percentage recovery obtained in the range of 96.8%–101.2% and the method is linear for impurity R for specified concentration range with coefficient of variation (r) not less than 0.99. acid, base, oxidation, thermal and photolytic degradation have been carried in drug substance and drug product. The proposed RP-HPLC method was found to be specific, linear, precise, accurate and robust.

 

Keywords: Tacrolimus, FK506, Thermal degradation impurity, Allyl ester rearrangement impurity, RP-HPLC

Cite this Article

J. Balaji, C. Nisha Shri. Development and Validation of RP-HPLC Method for Determination of Thermal Degradation Impurity in Tacrolimus Drug Substance and Drug Product. Research & Reviews: A Journal of Drug Formulation, Development and Production. 2016; 3(1): 14–19p.

Downloads

Published

2019-02-27

Issue

Vol. 3 No. 1 (2016)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.